Health Canada Approves Lenalidomide for Treatment of Multiple Myeloma
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Health Canada Approves Lenalidomide for Treatment of Multiple Myeloma

NEW YORK -- October 6, 2008 -- Health Canada has approved lenalidomide (Revlimid) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least 1 prior therapy.

The approval was based upon the safety and efficacy results of 2 large, randomised phase 3 trials; North American Trial MM-009 and International Trial MM-010, which evaluated lenalidomide plus dexamethasone in patients with multiple myeloma who had received at least 1 prior therapy.

SOURCE: Celgene

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities